세계의 길랭 바레 증후군(GBS) 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Guillain-Barre Syndrome (GBS) Market is presumed to reach the market size of nearly USD 1054.24 Million by 2032 from USD 672.62 Million in 2023 with a CAGR of 5.12% under the study period 2024-2032.

Guillain-Barre syndrome (GBS) is an uncommon autoimmune disorder in which the immune system targets the peripheral nerves, leading to muscle weakness and paralysis. Symptoms often begin with tingling & weakness in the legs and can progress to affect the entire body. An infection typically triggers GBS and requires medical treatment such as immunotherapy and physical therapy for recovery. Early diagnosis and intervention are vital for better outcomes.

MARKET DYNAMICS

The guillain-barre syndrome (GBS) market is driven by various factors influencing the diagnosis, treatment, and research associated with this condition. Spurring awareness among healthcare professionals and the public about guillain-barre syndrome (GBS)has led to earlier diagnosis and intervention, which is crucial for better patient outcomes. The rising prevalence of GBS, often linked to infections like the Zika virus and, more recently, COVID-19, has heightened the focus on this syndrome. Medical research and technology advances have improved the understanding of GBS, leading to more effective treatments and therapies. Immunoglobulin therapy and plasmapheresis, the primary treatments for GBS, have seen significant advancements, enhancing their efficacy and accessibility.

Government and private funding for rare disease research also supports the growth of the GBS market by fostering innovation and new treatment options. Furthermore, the increasing number of specialized healthcare facilities and the availability of advanced diagnostic tools contribute to the improved management of GBS. Collaborative efforts among healthcare providers, researchers, and patient advocacy groups are vital in driving awareness and supporting those affected by guillain-barre syndrome (GBS), propelling the market growth. However, limited awareness and late diagnosis in certain regions may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Guillain-Barre Syndrome (GBS). The growth and trends of Guillain-Barre Syndrome (GBS) industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Guillain-Barre Syndrome (GBS) market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

• First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis))
• Supportive treatment

By Type

• Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
• Miller Fisher Syndrome (MFS)
• Acute Motor Axonal Neuropathy (AMAN)
• Other Types

By Gender

• Male
• Female

By Age Group

• Below 20 years
• 21-40 years
• 41-59 years
• 60 and above

By End-user

• Hospitals
• Clinics
• Rehabilitation Centers
• Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Guillain-Barre Syndrome (GBS) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Guillain-Barre Syndrome (GBS) market include AbbVie Inc., Biogen Inc., Cadila Healthcare Limited, CSL Behring LLC, F.Hoffmann-La Roche Ltd., GSK Plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. GUILLAIN-BARRE SYNDROME (GBS) - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment Type
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By Gender
  • 3.7.4 Market Attractiveness Analysis By Age Group
  • 3.7.5 Market Attractiveness Analysis By End-user
  • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TREATMENT TYPE

• 5.1. Overview By Treatment Type
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Treatment Type
• 5.4. First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Historic and Forecast Sales By Regions
• 5.5. Supportive treatment Historic and Forecast Sales By Regions

6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TYPE

• 6.1. Overview By Type
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Type
• 6.4. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Historic and Forecast Sales By Regions
• 6.5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Historic and Forecast Sales By Regions
• 6.6. Miller Fisher Syndrome (MFS) Historic and Forecast Sales By Regions
• 6.7. Acute Motor Axonal Neuropathy (AMAN) Historic and Forecast Sales By Regions
• 6.8. Other Types Historic and Forecast Sales By Regions

7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GENDER

• 7.1. Overview By Gender
• 7.2. Historical and Forecast Data
• 7.3. Analysis By Gender
• 7.4. Male Historic and Forecast Sales By Regions
• 7.5. Female Historic and Forecast Sales By Regions

8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY AGE GROUP

• 8.1. Overview By Age Group
• 8.2. Historical and Forecast Data
• 8.3. Analysis By Age Group
• 8.4. Below 20 years Historic and Forecast Sales By Regions
• 8.5. 21-40 years Historic and Forecast Sales By Regions
• 8.6. 41-59 years Historic and Forecast Sales By Regions
• 8.7. 60 and above Historic and Forecast Sales By Regions

9. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY END-USER

• 9.1. Overview By End-user
• 9.2. Historical and Forecast Data
• 9.3. Analysis By End-user
• 9.4. Hospitals Historic and Forecast Sales By Regions
• 9.5. Clinics Historic and Forecast Sales By Regions
• 9.6. Rehabilitation Centers Historic and Forecast Sales By Regions
• 9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.3.2 North America By Segment Sales Analysis
  • 10.3.3 North America By Country Sales Analysis
  • 10.3.4 United States Sales Analysis
  • 10.3.5 Canada Sales Analysis
  • 10.3.6 Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.4.2 Europe By Segment Sales Analysis
  • 10.4.3 Europe By Country Sales Analysis
  • 10.4.4 United Kingdom Sales Analysis
  • 10.4.5 France Sales Analysis
  • 10.4.6 Germany Sales Analysis
  • 10.4.7 Italy Sales Analysis
  • 10.4.8 Russia Sales Analysis
  • 10.4.9 Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.5.2 Asia Pacific By Segment Sales Analysis
  • 10.5.3 Asia Pacific By Country Sales Analysis
  • 10.5.4 China Sales Analysis
  • 10.5.5 India Sales Analysis
  • 10.5.6 Japan Sales Analysis
  • 10.5.7 South Korea Sales Analysis
  • 10.5.8 Australia Sales Analysis
  • 10.5.9 South East Asia Sales Analysis
  • 10.5.10 Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.6.2 Latin America By Segment Sales Analysis
  • 10.6.3 Latin America By Country Sales Analysis
  • 10.6.4 Brazil Sales Analysis
  • 10.6.5 Argentina Sales Analysis
  • 10.6.6 Peru Sales Analysis
  • 10.6.7 Chile Sales Analysis
  • 10.6.8 Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 10.7.2 Middle East & Africa By Segment Sales Analysis
  • 10.7.3 Middle East & Africa By Country Sales Analysis
  • 10.7.4 Saudi Arabia Sales Analysis
  • 10.7.5 UAE Sales Analysis
  • 10.7.6 Israel Sales Analysis
  • 10.7.7 South Africa Sales Analysis
  • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE GUILLAIN-BARRE SYNDROME (GBS) COMPANIES

• 11.1. Guillain-Barre Syndrome (GBS) Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12. COMPANY PROFILES OF GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Market Concentration Rate
• 12.3. AbbVie Inc.
  • 12.3.1 Company Overview
  • 12.3.2 Company Revenue
  • 12.3.3 Products
  • 12.3.4 Recent Developments
• 12.4. Biogen Inc.
  • 12.4.1 Company Overview
  • 12.4.2 Company Revenue
  • 12.4.3 Products
  • 12.4.4 Recent Developments
• 12.5. Cadila Healthcare Limited
  • 12.5.1 Company Overview
  • 12.5.2 Company Revenue
  • 12.5.3 Products
  • 12.5.4 Recent Developments
• 12.6. CSL Behring LLC
  • 12.6.1 Company Overview
  • 12.6.2 Company Revenue
  • 12.6.3 Products
  • 12.6.4 Recent Developments
• 12.7. F.Hoffmann-La Roche Ltd.
  • 12.7.1 Company Overview
  • 12.7.2 Company Revenue
  • 12.7.3 Products
  • 12.7.4 Recent Developments
• 12.8. GSK Plc
  • 12.8.1 Company Overview
  • 12.8.2 Company Revenue
  • 12.8.3 Products
  • 12.8.4 Recent Developments
• 12.9. Grifols SA
  • 12.9.1 Company Overview
  • 12.9.2 Company Revenue
  • 12.9.3 Products
  • 12.9.4 Recent Developments
• 12.10. LGM Pharmaceuticals Inc.
  • 12.10.1 Company Overview
  • 12.10.2 Company Revenue
  • 12.10.3 Products
  • 12.10.4 Recent Developments
• 12.11. Merck & Co. Inc.
  • 12.11.1 Company Overview
  • 12.11.2 Company Revenue
  • 12.11.3 Products
  • 12.11.4 Recent Developments
• 12.12. Octapharma AG
  • 12.12.1 Company Overview
  • 12.12.2 Company Revenue
  • 12.12.3 Products
  • 12.12.4 Recent Developments
• 12.13. Pfizer Inc.
  • 12.13.1 Company Overview
  • 12.13.2 Company Revenue
  • 12.13.3 Products
  • 12.13.4 Recent Developments
• 12.14. Takeda Pharmaceutical Company Limited
  • 12.14.1 Company Overview
  • 12.14.2 Company Revenue
  • 12.14.3 Products
  • 12.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies